Drug intelligence / Profile preview

CA45

Development stage: Preclinical
Lead developer: Eliteimmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CA45 is a pan-ebolavirus monoclonal antibody discovered by Integrated BioTherapeutics (IBT). It functions by binding to a shared region on the Ebola virus surface glycoprotein fusion loop, thereby neutralizing Ebola, Sudan, and Bundibugyo viruses. The research leading to its discovery was funded by the US Defense Threat Reduction Agency (DTRA), the National Institute of Allergy and Infectious Disease (NIAID), and the Public Health Agency of Canada (PHAC). IBT has granted an exclusive license to Eliteimmune for the development of CA45 as a therapeutic countermeasure in the Chinese market.

Targets

EBOV GP IFL (Zaire ebolavirus glycoprotein internal fusion loop)

Beyond the preview

Go deeper on CA45.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CA45.

Explore the full profile